Abstract
Raltegravir is an integrase inhibitor (INI) licensed for clinical use and other INI are in advanced stage of development. Different resistance mutations in HIV integrase from patients using these antiretroviral drugs have been described and G148H/R/K, N155H and less frequently Y143C/H/R are considered major resistant mutations to raltegravir. Both Stanford Database and Geno2Pheno list F121Y as conferring intermediate resistance "in vitro" both to raltegravir and elvitegravir. We report for the first time the "in vivo" selection F121Y and evolution to Y143R in a 31years old male clade B HIV-1 infected patient failing a raltegravir-containing salvage regimen. Plasma samples nine months prior to raltegravir (RAL-Naïve) and at weeks 32, 40 and 88 after RAL-containing regimen were analyzed. Antiretroviral susceptibility was evaluated at Stanford and Geno2Pheno from sequences obtained with RT-PCR. After a Viral load at week 12 below 50 copies/mL, viremia raised at week 20 to 4.5log10. The emergence of F121Y was observed at week 32 and 40, alongside with L74I, T97A, Q137H and V151I. At week 88 F121Y was no longer detected, L74I and T97A were maintained and Y143R emerged. F121Y might be an alternative pathway to Y143R. Changing of RAL-...Continue Reading
References
Nov 6, 2007·Journal of Virology·Kazuya ShimuraMasao Matsuoka
Jul 16, 2008·Antiviral Research·Masanori KobayashiTamio Fujiwara
Jul 25, 2008·The New England Journal of Medicine·Roy T SteigbigelUNKNOWN BENCHMRK Study Teams
Jul 25, 2008·The New England Journal of Medicine·David A CooperUNKNOWN BENCHMRK Study Teams
Aug 16, 2008·Biochemistry·Jessica MarinelloYves Pommier
Aug 19, 2008·Journal of Virological Methods·Kristel Van LaethemAnne-Mieke Vandamme
Sep 4, 2008·Journal of Medicinal Chemistry·Vincenzo SummaMichael Rowley
Jan 24, 2009·AIDS·Filippo CanducciNicola Gianotti
Feb 18, 2009·The Journal of Antimicrobial Chemotherapy·Isabelle MaletAnne-Genevieve Marcelin
Mar 6, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Caroline Bittencourt PassaesMariza Gonçalves Morgado
Jul 21, 2009·Antiviral Research·Luis Menéndez-Arias
Aug 5, 2009·Antimicrobial Agents and Chemotherapy·Andrea LowMartin Markowitz
Nov 11, 2009·Antimicrobial Agents and Chemotherapy·Olivier DelelisJean-François Mouscadet
Apr 5, 2011·The Journal of Infectious Diseases·Jose-Luis BlancoRobert W Shafer
May 18, 2011·Antimicrobial Agents and Chemotherapy·S ReigadasM L Andréola
Jun 23, 2011·Infection and Drug Resistance·Jean L MbisaPatricia A Cane
Oct 11, 2011·The Journal of Infectious Diseases·Filippo CanducciMassimo Clementi
Oct 22, 2011·The Lancet Infectious Diseases·Jean-Michel MolinaUNKNOWN Study 145 Team
Oct 25, 2011·The Lancet Infectious Diseases·Jan van LunzenSherene Min
Citations
Dec 24, 2013·International Journal of Antimicrobial Agents·Jaqueline de Souza CavalcantiUNKNOWN São Paulo Salvage Workgroup
Apr 9, 2014·The Journal of Antimicrobial Chemotherapy·Isabelle MaletAnne-Geneviève Marcelin
Nov 12, 2014·The Journal of Antimicrobial Chemotherapy·Jaqueline de Souza CavalcantiLuis Fernando de Macedo Brigido
Aug 18, 2016·Infection·A ZoufalyE Puchhammer-Stoeckl
Feb 18, 2017·PloS One·Michael E AbramMichael D Miller
Oct 23, 2012·Current Opinion in Infectious Diseases·Anna Maria GerettiFrancesca Ceccherini-Silberstein
Sep 26, 2019·Frontiers in Microbiology·Lucas de Almeida MachadoAna Carolina Ramos Guimarães
Aug 24, 2021·European Journal of Medicinal Chemistry·Yue WangRenhua Fan